(Q36313712)

English

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Veronica Veschi

object named as

Veronica Veschi

2

0 references

Marialaura Petroni

object named as

Marialaura Petroni

1

0 references

author name string

Alberto Gulino

3

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Giuseppe Giannini

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

publication date

12 October 2012

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Frontiers in Oncology

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

141

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Mdm2 and MdmX partner to regulate p53.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Translating p53 into the clinic.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

p53 is a direct transcriptional target of MYCN in neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Autophagy regulation by p53.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Modelling Myc inhibition as a cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

High mobility group A1 is a molecular target for MYCN in human neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

MycN sensitizes neuroblastoma cells for drug-induced apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Targeted expression of MYCN causes neuroblastoma in transgenic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

30 September 2017

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

29 June 2018

MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3470040

22 September 2018

Absence of p53 gene mutations in primary neuroblastomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/23091802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PI3King on MYCN to improve neuroblastoma therapeutics

1 reference

https://pubmed.ncbi.nlm.nih.gov/23091802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeted molecular therapy for neuroblastoma: the ARF/MDM2/p53 axis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23091802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structural insights into the dual-targeting mechanism of Nutlin-3

1 reference

https://pubmed.ncbi.nlm.nih.gov/23091802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3389/FONC.2012.00141

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36313712&oldid=1625213492"